Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells

Gene Therapy volume 9, pages 972–979 (2002)Cite this article

Abstract

Conditionally replicating adenoviruses (CRADs) are a novel strategy in cancer treatment and clinical trials using CRADs targeted to tumor cells have been reported recently. We hypothesized that it would be possible to construct CRADs targeted to dividing endothelial cells, which are present in the tumor endothelium. We utilized the regulatory elements of Flk-1 and endoglin genes, which have been shown to be highly overexpressed in angiogenic endothelial cells, to construct two CRADs: Ad.Flk-1, which has adenoviral E1A gene under the control of the Flk-1 enhancer/promoter, and Ad.Flk-Endo, which harbors the same Flk-1 enhancer/promoter as Ad.Flk-1, plus it has the adenoviral E1B gene under control of the endoglin promoter. Viral titer measurements by plaque assay showed that in human umbilical vein endothelial cells (HUVECs), both CRADs replicated at levels comparable to that of wild-type adenovirus. In Flk-1 and endoglin negative Hep3B and A549 cells, however, the replication of Ad.Flk-1 and Ad.Flk-Endo was reduced by 30-fold and 600-fold, respectively. Cytotoxicity assays demonstrated that both CRADs killed HUVECs as effectively as wild-type adenovirus and their cytotoxicity in Hep3B and A549 cells was comparable to nonreplicating control adenovirus. Furthermore, there was a striking inhibition (83–91%) of capillary network formation in an in vitro angiogenesis assay when HUVECs were infected with Ad.Flk-1 or Ad.Flk-Endo as compared with the nonreplicating control virus. These results demonstrate that CRADs can be transcriptionally targeted to dividing endothelial cells with high specificity, and that the combined use of Flk-1 and endoglin regulatory elements has a synergistic effect on targeting specificity. This principle may be incorporated into novel therapeutic agents to develop anti-angiogenic treatment for cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Heise C, Kirn DH . Replication-selective adenoviruses as oncolytic agents J Clin Invest 2000 105: 847–851

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Alemany R, Balague C, Curiel DT . Replicative adenoviruses for cancer therapy Nat Biotechnol 2000 18: 723–727

    Article  CAS  PubMed  Google Scholar 

  3. Kirn D, Martuza RL, Zwiebel J . Replication-selective virotherapy for cancer: biological principles, risk management and future directions Nat Med 2001 7: 781–787

    Article  CAS  PubMed  Google Scholar 

  4. Hernandez-Alcoceba R, Pihalja M, Wicha MS, Clarke MF . A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors Hum Gene Ther 2000 11: 2009–2024

    Article  CAS  PubMed  Google Scholar 

  5. Hallenbeck PL et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma Hum Gene Ther 1999 10: 1721–1733

    Article  CAS  PubMed  Google Scholar 

  6. Kurihara T, Brough DE, Kovesdi I, Kufe DW . Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen J Clin Invest 2000 106: 763–771

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Yu DC et al. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts Cancer Res 1999 59: 4200–4203

    CAS  PubMed  Google Scholar 

  8. Rodriguez R et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells Cancer Res 1997 57: 2559–2563

    CAS  PubMed  Google Scholar 

  9. Heise C et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy Nat Med 2000 6: 1134–1139

    Article  CAS  PubMed  Google Scholar 

  10. Bischoff JR et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 1996 274: 373–376

    Article  CAS  PubMed  Google Scholar 

  11. Khuri FR et al. A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nat Med 2000 6: 879–885

    Article  CAS  PubMed  Google Scholar 

  12. Nemunaitis J et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial Cancer Res 2000 60: 6359–6366

    CAS  PubMed  Google Scholar 

  13. Folkman J . Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1995 1: 27–31

    Article  CAS  PubMed  Google Scholar 

  14. Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 1996 86: 353–364

    Article  CAS  PubMed  Google Scholar 

  15. Carmeliet P, Jain RK . Angiogenesis in cancer and other diseases Nature 2000 407: 249–257

    Article  CAS  PubMed  Google Scholar 

  16. Risau W . Mechanisms of angiogenesis Nature 1997 386: 671–674

    Article  CAS  PubMed  Google Scholar 

  17. Brower V . Tumor angiogenesis – new drugs on the block Nat Biotechnol 1999 17: 963–968

    Article  CAS  PubMed  Google Scholar 

  18. Feldman AL, Libutti SK . Progress in antiangiogenic gene therapy of cancer Cancer 2000 89: 1181–1194

    Article  CAS  PubMed  Google Scholar 

  19. Millauer B et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis Cell 1993 72: 835–846

    Article  CAS  PubMed  Google Scholar 

  20. Shalaby F . Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice Nature 1995 376: 62–66

    Article  CAS  PubMed  Google Scholar 

  21. Ferrara N . Vascular endothelial growth factor: molecular and biological aspects Curr Top Microbiol Immunol 1999 237: 1–30

    CAS  PubMed  Google Scholar 

  22. Plate KH et al. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis Cancer Res 1993 53: 5822–5827

    CAS  PubMed  Google Scholar 

  23. Kappel A et al. Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice Blood 1999 93: 4284–4292

    CAS  PubMed  Google Scholar 

  24. Heidenreich R, Kappel A, Breier G . Tumor endothelium-specific transgene expression directed by vascular endothelial growth factor receptor-2 (Flk-1) promoter/enhancer sequences Cancer Res 2000 60: 6142–6147

    CAS  PubMed  Google Scholar 

  25. Miller DW et al. Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells Int J Cancer 1999 81: 568–572

    Article  CAS  PubMed  Google Scholar 

  26. Rius C et al. Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1 Blood 1998 92: 4677–4690

    CAS  PubMed  Google Scholar 

  27. Burrows FJ et al. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy Clin Cancer Res 1995 1: 1623–1634

    CAS  PubMed  Google Scholar 

  28. Douglas JT et al. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors Cancer Res 2001 61: 813–817

    CAS  PubMed  Google Scholar 

  29. Thorpe PE, Burrows FJ . Antibody-directed targeting of the vasculature of solid tumors Breast Cancer Res Treat 1995 36: 237–251

    Article  CAS  PubMed  Google Scholar 

  30. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A . Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector J Virol 2000 74: 2567–2583

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Medina DJ et al. Adenovirus-mediated cytotoxicity of chronic lymphocytic leukemia cells Blood 1999 94: 3499–3508

    CAS  PubMed  Google Scholar 

  32. Osborne TF, Gaynor RB, Berk AJ . The TATA homology and the mRNA 5’ untranslated sequence are not required for expression of essential adenovirus E1A functions Cell 1982 29: 139–148

    Article  CAS  PubMed  Google Scholar 

  33. Elliott WL, Roberts BJ, Howard CT, Leopold WR . Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N’)platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo Cancer Res 1994 54: 4412–4418

    CAS  PubMed  Google Scholar 

  34. Vile RG, Russell SJ, Lemoine NR . Cancer gene therapy: hard lessons and new courses Gene Therapy 2000 7: 2–8

    Article  CAS  PubMed  Google Scholar 

  35. Denekamp J . Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy Br J Radiol 1993 66: 181–196

    Article  CAS  PubMed  Google Scholar 

  36. Mavria G, Porter CD . Reduced growth in response to ganciclovir treatment of subcutaneous xenografts expressing HSV-tk in the vascular compartment Gene Therapy 2001 8: 913–920

    Article  CAS  PubMed  Google Scholar 

  37. Roelvink PW et al. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae Science 1999 286: 1568–1571

    Article  CAS  PubMed  Google Scholar 

  38. Pasqualini R, Koivunen E, Ruoslahti E . Alpha v integrins as receptors for tumor targeting by circulating ligands Nat Biotechnol 1997 15: 542–546

    Article  CAS  PubMed  Google Scholar 

  39. Arap W, Pasqualini R, Ruoslahti E . Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model Science 1998 279: 377–380

    Article  CAS  PubMed  Google Scholar 

  40. Ronicke V, Risau W, Breier G . Characterization of the endothelium-specific murine vascular endothelial growth factor receptor-2 (Flk-1) promoter Circ Res 1996 79: 277–285

    Article  CAS  PubMed  Google Scholar 

  41. Bautista DS, Hitt M, McGrory J, Graham FL . Isolation and characterization of insertion mutants in E1A of adenovirus type 5 Virology 1991 182: 578–596

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by Department of Defense Grant DAMD 17-99-1-9307 (to BVS), Academy of Finland fellowship (to MJS) and Leiras Research Foundation Grant (to MJS). We wish to thank Dr Shu-Hsia Chen and Dr Simon Hall for helpful and constructive discussions.

Author information

Authors and Affiliations

  1. Institute for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, New York, NY, USA

    MJ Savontaus, BV Sauter, T-G Huang & SLC Woo

Authors
  1. MJ Savontaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. BV Sauter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T-G Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. SLC Woo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Savontaus, M., Sauter, B., Huang, TG. et al. Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. Gene Ther 9, 972–979 (2002). https://doi.org/10.1038/sj.gt.3301747

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301747

Keywords

Search

Advanced search

Quick links